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Objective(s): Multidrug resistance (MDR) of cancer cells is a major obstacle to successful 
chemotherapy. Overexpression of breast cancer resistance protein (BCRP) is one of the major causes of 
MDR. In addition, it has been shown that PI3K/Akt signaling pathway involves in drug resistance. 
Therefore, we evaluated the effects of novel approaches including siRNA directed against BCRP and 
targeted therapy against PI3K/Akt signaling pathway using LY294002 (LY) to re-sensitize breast 
cancer MCF7 cell line to mitoxantrone (MTX) chemotherapy.  
Materials and Methods: Anticancer effects of MTX, siRNA, and LY alone and in combination were 
evaluated in MCF7 cells using MTT cytotoxicity assay and flow cytometry analysis of cell cycle 
distribution and apoptosis induction.  
Results: MTT and apoptosis assays showed that both MTX and LY inhibited cell proliferation and 
induced apoptosis in MCF7 cells. Results indicated that inhibition of BCRP by siRNA or PI3K/Akt 
signaling pathway by LY significantly increased sensitivity of MCF7 cells to antiproliferation and 
apoptosis induction of MTX. Furthermore, MTX showed G2/M arrest, whereas LY induced G0/G1 
arrest in cell cycle distribution of MCF7 cells. Combination of siRNA or LY with MTX chemotherapy 
significantly increased accumulation of MCF7 cells in the G2/M phase of cell cycle.  
Conclusion: Combination of MTX chemotherapy with BCRP siRNA and PI3K/Akt inhibition can 
overcome MDR in breast cancer cells. This study furthermore suggests that novel therapeutic 
approaches are needed to enhance anticancer effects of available drugs in breast cancer.  
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Introduction 
Breast cancer is one of the most common human 
malignancies and the second leading cause of cancer-
related deaths in women (1, 2). Chemotherapy is still 
the most effective modality for the treatment of various 
types of cancers in a clinical setting (3). Successful 
chemotherapy is often hampered by the development 
of multidrug resistance (MDR) in tumor cells (4). MDR 
is characterized by cross-resistance to a broad 
spectrum of structurally and functionally unrelated 
cytotoxic agents (5). Various mechanisms are 
responsible for MDR in cancer cells that one of the main 
ones is associated with overexpression of ATP-binding 
cassette (ABC) transporters such as P-glycoprotein            
(P-gp), MDR-associated proteins (MRP) and breast 
cancer resistant protein (BCRP/ABCG2). These 
proteins actively pump out a broad spectrum of 
 
clinically relevant but structurally different compounds 
and decrease the intracellular drug accumulation (6). 
BCRP was first identified in a doxorubicin-resistant 
MCF-7 breast cancer cell line (7). It is a transporter 
consisting of a six transmembrane domain and one 
ATP-binding site. BCRP is widely expressed in a variety 
of normal tissues including placenta, breast, ovary, 
intestine, and liver, and it has been shown to play                  
an important role against xenobiotics and their 
metabolites (4, 7). BCRP has been considered as one of 
the major transporters responsible for drug resistance 
in cancer cells (7). Some examples of BCRP substrates 
include topotecan, SN-38, mitoxantrone (MTX),               
and flavopiridol (4, 8). MTX is a topoisomerase               
II targeting drug that has been used in combina-          
tion with other anti-cancer drugs for the clinical 
treatment of malignancy (9). 
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Overexpression of BCRP is associated with 
resistance to a wide range of different anticancer 
agents including MTX (6). There have been 
enormous efforts all over the world in the search for 
safe and effective inhibitors of the transporters as a 
novel strategy to overcome MDR. One specific 
approach to overcome MDR is application of the 
small interfering RNA (siRNA) that can direct 
sequence-specific degradation of target mRNA (i.e. 
BCRP/ABCG2), which in turn suppresses protein 
expression (10, 11). This is potentially an effective 
method in restoring drug sensitivity in cancer cells 
via MDR reversal (4). In addition, the PI3-kinase/Akt 
signaling pathway has been implicated as a key 
element in the regulation of a number of cellular 
functions such as cell cycle, cell proliferation and cell 
survival (1, 12). Also, in some of studies it has been 
shown that regulation of BCRP function and localization 
to the plasma membrane are mediated by Akt.                 
This pathway plays a major role not only in tumor 
development but also in the tumor’s potential response 
to cancer treatment. Activation of this pathway                 
has been shown to decrease sensitivity to 
chemotherapeutics resulting in diminished treatment 
success. The flavonoid derivative, LY294002 (LY), with 
the structure shown in Figure 1 is known as a specific 
inhibitor of the PI3K/Akt kinase pathway (13). It has 
been successfully used to enhance sensitivity of cancer 
cells to drug-induced apoptosis, and this effect has 
generally been mediated by its PI3K-Akt blocking 
activity (14). Therefore, inhibition of PI3K/Akt pathway 
has been considered as a strategy for targeted drug 
development. It has also been recently drawn 
considerable attention for combination therapy to 
achieve enhanced efficacy in drug-resistant cancer 
cells (1).  
In this study, siRNA therapy was used to inhibit 
BCRP expression in breast cancer MCF7 cell line to 
enhance anticancer effects of MTX chemotherapy. 
Also, we investigated the effect of LY alone and in 
combination with MTX on proliferation, apoptosis 
induction and cell cycle distribution of breast cancer 
MCF7 cell line. 
 
Materials and Methods 
Materials 
RPMI 1640 and fetal bovine serum (FBS) were 
purchased from Biosera (UK). Pen-strep and trypsin- 
EDTA were purchased from Gibco (UK). MTT (3-(4, 
5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium 
bromide), propidium iodide (PI), and Annexin V-FITC 
were purchased from Sigma (Germany). DAPI (4, 6-
diamidine-2-phenylindole) and Nonidet P40 were 
purchased from Roche (Germany). Mitoxantrone was 
provided from Ebewe (Austria). LY294002 was 
purchased from Chemeda (USA). 
 
 
 
Figure 1. Chemical structure of LY294002 
 
Cell culture 
The MCF7 cell line was purchased from cell bank 
of Pasteur Institute of Iran and cultured in RPMI1640 
supplemented with 10% heat-inactivated FBS, 100 
U/ml penicillin, and 100 mg/ml streptomycin and 
incubated at 37 °C in a humidified 5% CO2 incubator. 
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Figure 2. Cytotoxic effects of the MTX and LY on MCF7 cells  
The MCF7 cells were treated with different concentrations of MTX 
(A) and LY (B). After 48 hr and 72 hr of exposure, the cell 
proliferation was determined using MTT assay. Each experiment 
was repeated at least three times in quadruplicates for each 
concentration and the results were expressed as mean±SD. 
*denotes P<0.001 for significant difference between treatments in 
comparison to control RPMI 
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Drug preparation 
LY was initially solubilized in dimethylsulphoxide 
(DMSO) at a concentration of 10 mM, stored at 4 °C 
and protected from the light. Different 
concentrations of LY were then freshly prepared in 
complete culture medium before use and added to 
the cells in different experiments. In all experiments, 
DMSO concentration never exceeded 1% that has no 
effect on MCF7 cells. MTX (20 mg/ml) was diluted in 
complete culture medium freshly before use and 
added to the cells at different concentrations.  
 
MTT cytotoxicity assay 
Proliferation of MCF7 cells under different 
conditions was determined using the MTT assay. 
Briefly, 5000 MCF7 cells per well were seeded in 96-
well plates. After 48 hr, culture media was removed 
and the cells were treated with MTX, LY, 
siRNA/polymer alone and in combination at varying 
concentrations and time points. Then MTT solution 
(4 mg/ml in phosphate-buffered saline (PBS)) was 
added to each well. After 3 hr incubation at 37 °C at 
5% CO2, DMSO was added to each well to dissolve 
the formazan crystals, and the absorbance of each 
well was read at 540 nm using a microplate reader 
(Sunrise, Tecan, Switzerland). The results were 
presented as a percentage to the control RPMI. The 
growth inhibition rate was calculated using the 
following equation: inhibition rate (%) = ((OD)exp/ 
(OD)con)× 100 in which ODexp and ODcon represent the 
optical densities of treated and untreated control 
cells, respectively. Drug concentrations that inhibited 
cell proliferation to 50% of the control RPMI (IC50) 
were determined from at least three independent 
experiments in quadruplicate format for each 
treatment. 
 
siRNA preparation and transfection  
The siRNA duplex targeting, BCRP mRNA, was 
purchased from Qiagen (UK) with the following 
sequences: Sense: (GGU  CUA  AUU  UAU  UAA UCU A) 
dTdT, Antisense: (UAG AUU AAU  AAA UUA GAC C) 
dAdT. Briefly, 48 hr before transfection, cells were 
seeded in 96-well plates at a density of 5000 
cells/well and were exposed to Chitosan + Alginate 
polymer alone, siRNA alone as well as siRNA-
polymer (si+P) complex for 6 hr. Then transfection 
mixture was replaced with fresh culture medium or 
MTX. MCF7 cells were then incubated at 37 °C at 5% 
CO2 for 48 hr and cell proliferation was determined 
using the MTT assay. 
 
Apoptosis assay 
MCF7 cells were seeded into 6-well plates at a 
density of 2.5×105 cells/well. The cells were exposed 
to MTX, LY, siRNA-polymer (si+P) complex alone  
and in combination for 48 hr and then cells were 
harvested, washed twice with PBS, resuspended in 
binding buffer, and stained with Annexin V-FITC plus 
propidium iodide (PI) for 15 min at 4 °C in dark. 
Finally, stained cells were resuspended in binding 
buffer and assessed for apoptosis by Partec-PAS 
(Germany) flow cytometer, and data processed using 
Flowmax software. 
 
Cell cycle distribution analysis 
MCF7 cells were seeded into 6-well plates at a 
density of 2.5×105 cells/well. The cells were exposed 
to MTX, LY, siRNA-polymer (si+P) complex alone and 
in combination for 48 hr, and then cells were 
harvested, washed twice with PBS and stained with 
DAPI for 30 min at 4 °C in dark. Cell cycle distribution 
based on DNA content of cells was then determined 
by Partec-PAS flow cytometer, and data were 
processed using Flowmax software. 
 
Statistical analysis 
All experiments were repeated at least three 
times and data presented as mean±SD. One-way 
ANOVA with Tukey post hoc was used for multiple 
comparisons of data, and results were considered 
statistically significant at P<0.05. 
 
Results 
Cytotoxic effects of MTX or LY on MCF7 cells 
MTT assay was used to determine the effect of 
different treatments on cell proliferation of MCF7 
cells. Cell proliferation was significantly decreased 
following treatment of MCF7 cells with MTX or LY in 
a concentration- and time-dependent manner 
(Figure 2). The IC50 for MTX and LY alone was 
determined to be 600 nM and 15 µM after 48 hr 
treatment of MCF7 cells, respectively.  
 
Effect of down-regulation of BCRP by siRNA on 
sensitivity of MCF7 cells to MTX 
Given the association of BCRP expression with 
chemoresistance, we determined whether down-
regulation of BCRP using siRNA approach can re-
sensitize MCF7 cells to MTX chemotherapy. 
Treatment of MCF7 cells with Chitosan+Alginate 
(Polymer), siRNA, and siRNA-Polymer (si+P) 
complex alone did not significantly decrease cell 
proliferation in comparison to control RPMI. 
Whereas, combination of BCRP siRNA-Polymer 
(si+P) complex with 250 nM concentration of MTX 
(about 1/3 of MTX IC50) significantly reduced cell 
proliferation to 50% of control RPMI (Figure 3). This 
indicates that BCRP down-regulation by siRNA 
significantly reduced MTX IC50 by increasing 
retention of drug within the cancer cells to exert 
anticancer effects. This in turn, reduces the MTX side 
effects on normal cells.  
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Figure 3. Effect of siRNA against BCRP on the sensitivity of MCF 
cells to mitoxantrone 
The MCF7 cells were exposed to Chitosan + Alginate (Polymer), 
siRNA, siRNA-polymer (si+P) complex as well as combination of 
siRNA-polymer (si+P) complex with MTX 250 nM for 6 hr as 
described in the methods. Then MCF7 cells were incubated with 
RPMI or MTX for 48 hr and then cytotoxicity was determined by 
MTT assay. Each experiment was repeated at least three times in 
quadruplicates for each treatment and the results are expressed as 
mean±SD. *denotes P<0.001 for significant difference between 
treatments in comparison to control RPMI 
 
Cytotoxicity of combination of LY and MTX on 
MCF7 cells 
We also assessed the efficacy of MTX in combination 
with PI3K/Akt signaling inhibitor on MCF7 cells. Co-
treatment of MCF7 cells with LY and MTX resulted in 
significant sensitization of these cells to MTX 
chemotherapy (Figure 4). Similar to BCRP siRNA, LY 
significantly reduced the IC50 of MTX from 600 nM to 
250 nM. This indicates synergistic effects between 
MTX and LY that enhances anticancer effects as well 
as reduced side effects of MTX chemotherapy on 
normal cells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Apoptosis induction in MCF7 cells  
The MCF7 cells were treated with mitoxantrone, LY, and siRNA-
polymer (si+P) complex alone and in combination for 48 hr to 
evaluate induction of apoptosis using Annexin V-FITC/PI double-
staining by flow cytometry. The percentage of early and late 
apoptotic cells were presented for each treatment group. Data are 
expressed as means ± SD of three independent experiments. 
*denotes P<0.001 and # P<0.01 for significant difference between 
treatments in comparison to control RPMI 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Effects of LY on mitoxantrone cytotoxicity in MCF7 cells  
The MCF7 cells were co-treated with specified concentrations of 
LY + MTX. After 48 hr and 72 hr of exposure, the cell proliferation 
was determined using MTT assay. Each experiment was repeated 
at least three times in quadruplicates for each treatment and the 
results are expressed as mean±SD. *denotes P<0.001 for 
significant difference between treatments in comparison to 
control RPMI 
 
Apoptosis 
In order to study the induction of apoptosis, 
MCF7 cells were treated with MTX, LY, and siRNA-
polymer (si+P) complex alone and in combination 
and analyzed by flow cytometry after double-
staining with AnnexinV-FITC and PI. Results of flow 
cytometry analysis showed the percentage of 
necrotic (Q1: AnnexinV-FITC-/PI+), late apoptotic 
(Q2: AnnexinV-FITC+/PI+), viable (Q3: AnnexinV-
FITC-/PI-), and early apoptotic (Q4: AnnexinV-
FITC+/PI-) cells. The early and late apoptosis rates  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Cell cycle alterations in MCF7 cells 
The MCF7 cells were treated with mitoxantrone, LY, and siRNA-
polymer (si+P) complex alone and in combination for 48 hr and 
stained with DAPI and analyzed by flow cytometry to determine 
cell cycle distribution pattern. Data are presented as the mean±SD 
and each experiment was repeated at least three times in triplicate 
formats. *denotes P<0.001, # P<0.01 and & P<0.05 for significant 
difference between treatments in comparison to control RPMI 
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together for the control RPMI was 3.82%, while those 
of the MTX 250 nM, MTX 600 nM and LY  15 M groups 
were 19.63%, 46.18%, and 42.50%, respectively 
(Figure 5). Interestingly, the percentage of early and 
late apoptotic cells in siRNA-polymer (si+P) 
complex+MTX 250 nM treated cells significantly 
increased to percentage similar to MTX 600 nM 
(43.56% versus 46.18%, respectively). Co-treatment of 
MTX 250 nM with half IC50 of LY 7.5 µM significantly 
increased apoptosis induced by MTX250 nM alone                 
to percentage similar to MTX 600 nM (40.11%                     
versus 46.18%, respectively). These results revealed 
that down-regulation of BCRP by siRNA or PI3K/                
Akt inhibition by LY significantly enhanced the 
sensitivity of MCF7 cells to apoptosis induction by MTX 
chemotherapy. 
 
Cell cycle distribution 
The effect of MTX, LY, and siRNA-polymer (si+P) 
complex alone and in combination on cell cycle 
distribution of MCF7 cells was determined by flow 
cytometry. Approximately, 57.47% of control RPMI 
cells were in G0/G1 phase, 29.19% in S phase and 
13.35% in G2/M phase (Figure 6). Compared with 
control RPMI cells, MTX induced cell accumulation in 
the G2/M phase while reducing the number of cells in 
G0/G1 and S phase. The G2/M cells accumulation in 
MCF7 cells increased from 13.35% in control RPMI to 
44.50% for MTX 250 nM and 54.58% for MTX 600 nM. 
Further increase in G2/M cells accumulation (50.19%) 
was observed in MCF7 cells treated with siRNA-
polymer (si+P) complex + MTX 250 nM in comparison 
to MTX 250 nM alone. Unlike MTX, LY 15 µM induced 
G0/G1 cells accumulation in comparison to                   
control RPMI (76.02% versus 57.47%, respectively). 
Distribution pattern of cell cycle changed following 
treatment of MCF7 cells with MTX 250 nM + LY 7.5 µM 
in comparison to LY 15 µM alone.  
 
Discussion 
Drug resistance is one of the clinical challenges in 
cancer treatment, which usually leads to the failure 
in cancer therapy or recurrence due to an incomplete 
elimination of the tumor cells (15). Acting as an 
efflux pump in tumor cells, overexpression of BCRP 
leads to reduced intracellular drug concentration 
and decreased cytotoxicity. In this study, MTX has 
been chosen to study drug resistance phenomenon 
due to its common use as anticancer chemotherapy 
agent (15). MTX resistance has been contributed to 
overexpression of various ABC transporters and in 
particular the BCRP. There are some chemical 
inhibitors of BCRP, such as Fumitremorgin C and 
GF120918, but their inhibitory effects are not 
clinically satisfactory. Therefore, developing less 
toxic and more efficient strategies are needed to 
overcome MDR mediated by BCRP (16). On the           
other hand, gene expression silencing approach 
using siRNA molecules has also been investigated in 
many studies. In this study, we evaluated 
effectiveness of siRNA to down-regulate BCRP 
expression as a strategy to re-sensitize MCF7 breast 
cancer cells to MTX. In order to confirm the effects of 
BCRP suppression on enhanced anticancer effects of 
chemotherapy, cytotoxicity, apoptosis induction and 
cell cycle changes were determined in MCF7 cells. 
MTX displayed a time- and concentration-dependent 
inhibition of cell proliferation. In the current study, 
we found that siRNA directed against BCRP 
significantly increased inhibitory effects of MTX on 
proliferation of MCF7 cells. Also, the rate of 
apoptosis induction by siRNA-polymer (si+P) + MTX 
250nM was as high as that induced by MTX 600 nM. 
This is in agreement with published data that 
showed knockdown of BCRP by siRNAs increased the 
sensitivity of human choriocarcinoma BeWo cells to 
MTX (4). Additionally, in the present study we 
examined the effects of MTX alone or in combination 
with siRNA on cell cycle pattern of MCF7 cells. 
Consistent with the findings of Seifrtova M (17), in 
this study MCF7 cells were mostly arrested in G2/M 
phase when treated with MTX. Combination of 
siRNA-polymer (si+P) with MTX 250 nM further 
increased the percentage of cell accumulation in 
G2/M phase similar to MTX 600 nM. The induction of 
cell cycle arrest and apoptosis by chemotherapeutic 
agents could be an effective strategy to prevent the 
uncontrolled cell proliferation and the survival of 
cancerous cells. 
Recent data have suggested the involvement of 
PI3K/Akt activity in controlling MDR (18). Since            
this pathway is important target for therapeutic 
interference, we sought to investigate whether 
blocking this pathway by LY294002, a PI3K-specific 
inhibitor, would result in a sensitization of cancer 
cells to chemotherapy. Consistent with the findings 
of Jiang et al (19) who showed that LY294002 
inhibited cell proliferation and induced apoptosis in 
CNE-2Z cells, our results showed that LY markedly 
inhibited MCF7 cell proliferation and induced 
apoptosis. Furthermore, similar to findings of 
YangJiong et al (20), we found that co-treatment of 
MCF7 cells with MTX and LY significantly enhanced 
cytotoxicity of MTX on MCF7 cells. To test whether 
the anti-proliferative effects of LY was related to cell 
cycle arrest, the cycle progression was examined by 
the flow cytometry. Previous studies demonstrated 
that LY induces apoptosis and G0/G1 cell cycle arrest 
(21). Similarly in our study, LY showed cell cycle 
arrest in G0/G1 phase. Also, we observed that 
apoptosis rate induced by MTX 250nM was increased 
in the presence of the PI3/Akt signaling inhibitor  
(LY 7.5 µM) similar to the percentage of MTX 600 
nM. In addition, MCF7 cells were arrested at G2/M 
phase following co-treatment of MTX 250 nM with 
LY 7.5 µM. The effect of LY on MTX cytotoxicity could 
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be due to the suppression of BCRP via the inhibition 
of the PI3K/Akt signaling pathway that resulted in 
increase in the intracellular drug accumulation. 
 
Conclusion 
Taken together, this research further confirmed the 
role of BCRP in drug resistance of breast cancer cells 
and showed that siRNA against BCRP can re-sensitize 
human MCF7 breast cancer cell line against MTX 
chemotherapy. This suggests that siRNA therapy can be 
an effective strategy for prevention and reversion of 
MDR in cancer, and may potentially be of interest               
for future combination of chemotherapy and gene 
therapy approaches. In this study, our findings 
demonstrated that LY is also able to sensitize the MCF7 
cells to MTX treatment, highlighting the importance of 
PI3K/AKT signaling pathway in the resistance of breast 
cancer cells to chemotherapy. However, further studies 
including in vivo evaluations are needed to verify 
clinical effectiveness of these combination therapies              
to enhance anticancer effects of available chemo-
therapeutic agents in cancer cells. 
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